Royalty Pharma raises 2026 Portfolio Receipts guidance to $3,500-3,550 million
FROM THE WIRE · GLOBENEWSWIRE.COM
Portfolio Receipts growth of 9% to $890 million; Royalty Receipts growth of 9% Net cash provided by operating activities of $686 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE)…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA second guidance raise with 9% receipts growth is a positive signal for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third quarter Portfolio Receipts grew 9% to $890 million.
- 02Net cash from operating activities was $686 million.
- 03Full year 2026 Portfolio Receipts guidance was raised to $3,500-3,550 million.
- 04CEO Pablo Legorreta called the third quarter results excellent.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets